- Home
- NBIX vs RNR Comparison
NBIX vs RNR Comparison
Compare NBIX & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- RNR
- Stock Information
- Founded
- NBIX 1992
- RNR 1993
- Country
- NBIX United States
- RNR Bermuda
- Employees
- NBIX N/A
- RNR N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- RNR Property-Casualty Insurers
- Sector
- NBIX Health Care
- RNR Finance
- Exchange
- NBIX Nasdaq
- RNR Nasdaq
- Market Cap
- NBIX 12.8B
- RNR 12.3B
- IPO Year
- NBIX 1996
- RNR 1995
- Fundamental
- Price
- NBIX $120.17
- RNR $258.44
- Analyst Decision
- NBIX Buy
- RNR Buy
- Analyst Count
- NBIX 24
- RNR 10
- Target Price
- NBIX $165.09
- RNR $267.50
- AVG Volume (30 Days)
- NBIX 1.1M
- RNR 247.0K
- Earning Date
- NBIX 10-29-2024
- RNR 10-30-2024
- Dividend Yield
- NBIX N/A
- RNR 0.60%
- EPS Growth
- NBIX 89.41
- RNR 503.16
- EPS
- NBIX 3.29
- RNR 50.56
- Revenue
- NBIX $2,119,500,000.00
- RNR $10,562,208,000.00
- Revenue This Year
- NBIX $25.59
- RNR N/A
- Revenue Next Year
- NBIX $16.79
- RNR $3.01
- P/E Ratio
- NBIX $36.49
- RNR $5.11
- Revenue Growth
- NBIX 26.69
- RNR 42.85
- 52 Week Low
- NBIX $103.63
- RNR $188.24
- 52 Week High
- NBIX $157.98
- RNR $261.62
- Technical
- Relative Strength Index (RSI)
- NBIX 27.49
- RNR 71.46
- Support Level
- NBIX $119.76
- RNR $253.90
- Resistance Level
- NBIX $129.68
- RNR $261.62
- Average True Range (ATR)
- NBIX 4.00
- RNR 4.04
- MACD
- NBIX -3.16
- RNR 0.62
- Stochastic Oscillator
- NBIX 1.17
- RNR 84.67
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.